The U.S. intravenous solutions market size was estimated at USD 4.9 billion in 2025 and is projected to reach USD 9.8 billion by 2033, growing at a CAGR of 9.4% from 2026 to 2033. The market growth is driven by an aging population needing medical interventions, a surge in chronic diseases requiring advanced treatments, and enhancements in healthcare technology that elevate patient care.
This sector's growth reflects the critical need for innovative healthcare solutions to address the complex demands of modern medicine. The increasing incidence of cancer is a key driver for the U.S. intravenous solutions industry, as cancer patients frequently require IV therapy for chemotherapy administration, hydration, electrolyte balance, and supportive care. For instance, the American Cancer Society estimated that in 2026, around 60,480 new cases of oral cavity or oropharyngeal cancer and about 13,150 related deaths will be recorded, highlighting the growing patient pool requiring continuous IV-based treatment and nutritional support.
The rising use of immunonutrition formulas is driving growth in the U.S. IV solutions market, particularly in post-surgical recovery and critical care settings. These specialized parenteral formulations are designed to enhance immune response, reduce infection risk, and improve clinical outcomes in trauma, surgical, and critically ill patients. Products such as Elemune by Otsuka Holdings Co., Ltd., which contains L-alanyl-L-glutamine, are widely used for metabolic and immune support in infection and trauma cases. Similarly, SMOFlipid and Omegaven by Fresenius Kabi AG provide lipid-based nutrition enriched with omega-3 fatty acids, supporting energy requirements and reducing inflammation in ICU patients with limited enteral feeding. The growing clinical emphasis on improved recovery outcomes and reduced hospital stays is driving the adoption of advanced IV nutritional solutions across U.S. healthcare settings.
This sector's growth reflects the critical need for innovative healthcare solutions to address the complex demands of modern medicine. The increasing incidence of cancer is a key driver for the U.S. intravenous solutions industry, as cancer patients frequently require IV therapy for chemotherapy administration, hydration, electrolyte balance, and supportive care. For instance, the American Cancer Society estimated that in 2026, around 60,480 new cases of oral cavity or oropharyngeal cancer and about 13,150 related deaths will be recorded, highlighting the growing patient pool requiring continuous IV-based treatment and nutritional support.
The rising use of immunonutrition formulas is driving growth in the U.S. IV solutions market, particularly in post-surgical recovery and critical care settings. These specialized parenteral formulations are designed to enhance immune response, reduce infection risk, and improve clinical outcomes in trauma, surgical, and critically ill patients. Products such as Elemune by Otsuka Holdings Co., Ltd., which contains L-alanyl-L-glutamine, are widely used for metabolic and immune support in infection and trauma cases. Similarly, SMOFlipid and Omegaven by Fresenius Kabi AG provide lipid-based nutrition enriched with omega-3 fatty acids, supporting energy requirements and reducing inflammation in ICU patients with limited enteral feeding. The growing clinical emphasis on improved recovery outcomes and reduced hospital stays is driving the adoption of advanced IV nutritional solutions across U.S. healthcare settings.
U.S. Intravenous Solutions Market Report Segmentation
This report forecasts revenue & volume growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. intravenous solutions market report based on type, nutrients, and end use:- Type Outlook (Volume, Thousand Units; Revenue, USD Million, 2021-2033)
- Total Parenteral Nutrition
- Peripheral Parenteral Nutrition
- Nutrients Outlook (Volume, Thousand Units; Revenue, USD Million, 2021-2033)
- Carbohydrates
- Vitamins & Minerals
- Single-dose Amino Acids
- Parenteral Lipid Emulsion
- Others
- End Use Outlook (Volume, Thousand Units; Revenue, USD Million, 2021-2033)
- Home
- Hospitals
- Infusion Centers
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Intravenous Solutions Market: Product Estimates & Trend Analysis
Chapter 5. Intravenous Solutions Market: Nutrient Estimates & Trend Analysis
Chapter 6. Intravenous Solutions Market: End Use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Fresenius Kabi AG
- B. Braun SE
- Baxter
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer, Inc.
- JW Life Science
- CSL Vifor (formerly Vifor Pharma)
- ICU Medical, Inc.
- Amphastar Pharmaceuticals, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 4.9 Billion |
| Forecasted Market Value ( USD | $ 9.8 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | United States |
| No. of Companies Mentioned | 9 |
